Tags : Vir

Insights+

Insights+: Key Deals of JP Morgan Healthcare Conference 2021

This year J.P. Morgan 39th Annual Healthcare Conference was conducted virtually and we witnessed multiple announcements from numerous Biopharma companies An analysis of events and catalysts that were announced at the conference during these days are included in the report. Most of the deals occurred in the first two days of the conference Our PharmaShots […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Jan 11- 15, 2021)

Novartis’ Ligelizumab (QGE031) Receives the US FDA’s Breakthrough Designation for Patients with Chronic Spontaneous Urticaria Published: Jan 15, 2020 | Tags: Novartis, ligelizumab, (QGE031), Receives, US, FDA, Breakthrough designation, chronic spontaneous urticaria (CSU) Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment Published: Jan 15, 2020 | Tags: Philips, Merck KGaA, Personalized Fertility Treatment, […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2.  Celltrion Enters the Next Phase of Development for its Antiviral Therapy to Combat COVID-19 Pandemic Published: Apr 03, 2020 | Tags: Celltrion, Enters, Next Phase, Development, Antiviral Therapy, Combat, COVID-19 Pandemic 3. […]Read More

COVID-19 Pharma

Vir and Alnylam Expand Their Existing Collaboration to Develop RNAi

Shots: The collaboration will evaluate RNAi therapeutics targeting three host factors required for SARS-CoV-2 infection, including ACE2 and TMPRSS2. The third target is expected to emerge from Vir’s ongoing genomics efforts for identifying novel host factors relevant to COVID-19 Under the amended collaboration, Vir will be responsible for the development of selected DCs and the […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (March 02-06, 2020)

1. Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19 Published: Mar 06, 2020 | Tags: Mount Sinai, Signs, Multi-Year, Collaboration, Harbour BioMed, Develop, Novel Biotherapies, Multiple Cancer Indications, COVID-19 2. AstraZeneca Reports Results of Imfinzi and Tremelimumab in P-III DANUBE Study for Unresectable Stage IV […]Read More

Biotech COVID-19

Vir and Alnylam Expand their 2017 License Agreement to Target

Shots: The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious disease expertise Vir will be responsible for all development and commercialization of any selected DCs while Alnylam has an option to share equal profits & […]Read More